These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 17664324)

  • 1. Targeting fatty acid biosynthesis for the development of novel chemotherapeutics against Mycobacterium tuberculosis: evaluation of A-ring-modified diphenyl ethers as high-affinity InhA inhibitors.
    Boyne ME; Sullivan TJ; amEnde CW; Lu H; Gruppo V; Heaslip D; Amin AG; Chatterjee D; Lenaerts A; Tonge PJ; Slayden RA
    Antimicrob Agents Chemother; 2007 Oct; 51(10):3562-7. PubMed ID: 17664324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High affinity InhA inhibitors with activity against drug-resistant strains of Mycobacterium tuberculosis.
    Sullivan TJ; Truglio JJ; Boyne ME; Novichenok P; Zhang X; Stratton CF; Li HJ; Kaur T; Amin A; Johnson F; Slayden RA; Kisker C; Tonge PJ
    ACS Chem Biol; 2006 Feb; 1(1):43-53. PubMed ID: 17163639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Formulation studies of InhA inhibitors and combination therapy to improve efficacy against Mycobacterium tuberculosis.
    Knudson SE; Cummings JE; Bommineni GR; Pan P; Tonge PJ; Slayden RA
    Tuberculosis (Edinb); 2016 Dec; 101():8-14. PubMed ID: 27865404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent Advances and Structural Features of Enoyl-ACP Reductase Inhibitors of Mycobacterium tuberculosis.
    Inturi B; Pujar GV; Purohit MN
    Arch Pharm (Weinheim); 2016 Nov; 349(11):817-826. PubMed ID: 27775177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and synthesis of thiourea-based derivatives as Mycobacterium tuberculosis growth and enoyl acyl carrier protein reductase (InhA) inhibitors.
    Doğan ŞD; Gündüz MG; Doğan H; Krishna VS; Lherbet C; Sriram D
    Eur J Med Chem; 2020 Aug; 199():112402. PubMed ID: 32417538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First triclosan-based macrocyclic inhibitors of InhA enzyme.
    Rodriguez F; Saffon N; Sammartino JC; Degiacomi G; Pasca MR; Lherbet C
    Bioorg Chem; 2020 Jan; 95():103498. PubMed ID: 31855823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of Mycobacterium tuberculosis InhA: Design, synthesis and evaluation of new di-triclosan derivatives.
    Armstrong T; Lamont M; Lanne A; Alderwick LJ; Thomas NR
    Bioorg Med Chem; 2020 Nov; 28(22):115744. PubMed ID: 33007556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors.
    am Ende CW; Knudson SE; Liu N; Childs J; Sullivan TJ; Boyne M; Xu H; Gegina Y; Knudson DL; Johnson F; Peloquin CA; Slayden RA; Tonge PJ
    Bioorg Med Chem Lett; 2008 May; 18(10):3029-33. PubMed ID: 18457948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, chemical synthesis of 3-(9H-fluoren-9-yl)pyrrolidine-2,5-dione derivatives and biological activity against enoyl-ACP reductase (InhA) and Mycobacterium tuberculosis.
    Matviiuk T; Rodriguez F; Saffon N; Mallet-Ladeira S; Gorichko M; de Jesus Lopes Ribeiro AL; Pasca MR; Lherbet C; Voitenko Z; Baltas M
    Eur J Med Chem; 2013; 70():37-48. PubMed ID: 24140915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis of 3-heteryl substituted pyrrolidine-2,5-diones via catalytic Michael reaction and evaluation of their inhibitory activity against InhA and Mycobacterium tuberculosis.
    Matviiuk T; Mori G; Lherbet C; Rodriguez F; Pasca MR; Gorichko M; Guidetti B; Voitenko Z; Baltas M
    Eur J Med Chem; 2014 Jan; 71():46-52. PubMed ID: 24269516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New direct inhibitors of InhA with antimycobacterial activity based on a tetrahydropyran scaffold.
    Pajk S; Živec M; Šink R; Sosič I; Neu M; Chung CW; Martínez-Hoyos M; Pérez-Herrán E; Álvarez-Gómez D; Álvarez-Ruíz E; Mendoza-Losana A; Castro-Pichel J; Barros D; Ballell-Pages L; Young RJ; Convery MA; Encinas L; Gobec S
    Eur J Med Chem; 2016 Apr; 112():252-257. PubMed ID: 26900657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and biological activities of triazole derivatives as inhibitors of InhA and antituberculosis agents.
    Menendez C; Gau S; Lherbet C; Rodriguez F; Inard C; Pasca MR; Baltas M
    Eur J Med Chem; 2011 Nov; 46(11):5524-31. PubMed ID: 21944473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and evaluation of novel molecules with a diphenyl ether nucleus as potential antitubercular agents.
    Yang Y; Wang Z; Yang J; Yang T; Pi W; Ang W; Lin Y; Liu Y; Li Z; Luo Y; Wei Y
    Bioorg Med Chem Lett; 2012 Jan; 22(2):954-7. PubMed ID: 22197389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A slow, tight binding inhibitor of InhA, the enoyl-acyl carrier protein reductase from Mycobacterium tuberculosis.
    Luckner SR; Liu N; am Ende CW; Tonge PJ; Kisker C
    J Biol Chem; 2010 May; 285(19):14330-7. PubMed ID: 20200152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, and evaluation of novel diphenyl ether derivatives against drug-susceptible and drug-resistant strains of Mycobacterium tuberculosis.
    Kar SS; Bhat VG; Shenoy VP; Bairy I; Shenoy GG
    Chem Biol Drug Des; 2019 Jan; 93(1):60-66. PubMed ID: 30118192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rational design and synthesis of novel diphenyl ether derivatives as antitubercular agents.
    Kar SS; Bhat G V; Rao PP; Shenoy VP; Bairy I; Shenoy GG
    Drug Des Devel Ther; 2016; 10():2299-310. PubMed ID: 27486307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of novel InhA reductase inhibitors: application of pharmacophore- and shape-based screening approach.
    Kumar UC; Bvs SK; Mahmood S; D S; Kumar-Sahu P; Pulakanam S; Ballell L; Alvarez-Gomez D; Malik S; Jarp S
    Future Med Chem; 2013 Mar; 5(3):249-59. PubMed ID: 23464516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, in silico and in vitro evaluation of novel diphenyl ether derivatives as potential antitubercular agents.
    Tiwari AP; Sridhar B; Boshoff HI; Arora K; Gautham Shenoy G; Vandana KE; Varadaraj Bhat G
    Mol Divers; 2020 Nov; 24(4):1265-1279. PubMed ID: 31506871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological evaluation of potent triclosan-derived inhibitors of the enoyl-acyl carrier protein reductase InhA in drug-sensitive and drug-resistant strains of Mycobacterium tuberculosis.
    Stec J; Vilchèze C; Lun S; Perryman AL; Wang X; Freundlich JS; Bishai W; Jacobs WR; Kozikowski AP
    ChemMedChem; 2014 Nov; 9(11):2528-37. PubMed ID: 25165007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In Vitro Antimycobacterial Activity and Physicochemical Characterization of Diaryl Ether Triclosan Analogues as Potential InhA Reductase Inhibitors.
    Ibrahim TS; Taher ES; Samir E; M Malebari A; Khayyat AN; Mohamed MFA; Bokhtia RM; AlAwadh MA; Seliem IA; Asfour HZ; Alhakamy NA; Panda SS; Al-Mahmoudy AMM
    Molecules; 2020 Jul; 25(14):. PubMed ID: 32650556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.